Navigation Links
Barnett Releases Reference Guide on Form FDA 1572--Statement of Investigator
Date:10/11/2008

Barnett International, a division of Cambridge Healthtech Institute (CHI), has announced the release of The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors. Designed for clinical investigators, clinical site staff, study monitors, regulatory affairs professionals, and others involved in the clinical research process, the text is the first reference guide to address the Form FDA 1572-Statement of Investigator form, a critical regulatory document that well over 20,000 clinical investigators complete and sign each year before participating in FDA-regulated clinical trials.

Needham, MA (PRWEB) October 11, 2008 -- The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors addresses an emerging reality in clinical research today: As the number of FDA-issued warning letters to clinical investigators has risen in recent years, so too have citations regarding investigators' failure to complete the 1572 appropriately and correctly.

This new, state-of-the-art reference guide was developed to help not only experienced clinical investigators, who continue to struggle with addressing emerging trial-related complexities of modern clinical trials in the 1572, but the growing number of investigators who are conducting their first FDA-regulated trials each year. In addition to the FDA's emerging expectations regarding the 1572, the new reference guide directly addresses new 1572-related challenges facing clinical investigators and industry trial sponsors, including: the implications of what the FDA calls the "dispersing of study functions;" Norway's recent ban against the 1572; the evolution of the "subinvestigator" concept; and the increasing role of non-U.S. clinical investigators in FDA-regulated clinical trials.

The Form FDA 1572 reference guide addresses the most often-asked--but never answered--questions and also explores emerging areas of uncertainty related to the growing complexity of today's clinical trials, including:

  • When must a non-US clinical investigator sign a 1572?
  • How can a clinical investigator determine when a member of the site staff should be identified as a "subinvestigator"?
  • What are the legal/regulatory implications of signing a 1572--is it a legal contract?
  • When can a sponsor consider a clinical investigator to meet the "appropriate expert" standard?
  • What do we do now that at least one foreign country has banned the use of the 1572 for its clinical investigators?
  • How should "co-investigators" be handled in the 1572?
  • Must clinical investigators sign 1572s for "satellite sites"?
  • What must a study sponsor do beyond "collecting the paper" in the 1572 process?

The Form FDA 1572: A Reference Guide for Clinical Researchers, Sponsors, and Monitors is available from Barnett Educational Services for $45 per copy (bulk discounts available) by calling 1-800-856-2556 or click here to order your copy today.

About Barnett International
Barnett International is a recognized leader in clinical education and training for all levels of staff involved in the drug development process. In addition, Barnett is the publisher of the GCP Q&A Guide, the PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook, and other well-known reference manuals that help research facilities ensure compliance by providing updates about the latest federal regulations, while offering executives valuable information garnered from real-world studies, analyses, and widely respected industry opinion leaders. For more information on Barnett's publications and educational programs, visit www.barnettinternational.com

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) (www.chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Pharmaceutical Strategy Series, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

###

Read the full story at http://www.prweb.com/releases/2008/10/prweb1450214.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Downtown Emergency Service Center Releases CHASERS, Free Software for Homeless Service Management and Beyond
2. USP releases first certified reference material
3. change:healthcare CEO Releases 'My Healthcare is Killing Me'
4. AHRQ Releases Two New Resources to Help Consumers and Clinicians Prevent Dangerous Blood Clots
5. Sodexo Releases Innovative Prepaid Incentive Card Powered by eCommLink
6. Z Trim Holdings, Inc. Releases Letter to Shareholders
7. Mindray Releases Historical Financial Results Converted into US Dollar Terms
8. Pennsylvania Trauma Systems Foundation Releases Data Supporting Mandatory Use of Motorcycle Helmets
9. URAC Releases Revised Standards For Nine Health Care Management Accreditation Programs
10. ABC Releases Monograph on Scientific Research of POM Wonderful(R) Pomegranate Juice
11. ProSanos Corporation Releases New Software System to Improve Patient Safety via Surveillance and Analysis of Claims and Electronic Health Records
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: